Results 131 to 140 of about 56,599 (248)

International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Dermatologists worldwide reached consensus on criteria for dose reduction (DR) of biologics for psoriasis resulting in a DR algorithm for adalimumab, etanercept and ustekinumab. DR of IL‐17 and IL‐23 inhibitors was deemed feasible as well. This first international consensus provides essential information for uptake of biologic DR for psoriasis globally.
C. A. M. van Riel, W.‐H. Boehncke, J. L. W. Lambert, P. I. Spuls, L. S. van der Schoot, I. van Ee, E. M. G. J. de Jong, J. M. P. A. van den Reek, on behalf of the eDelphi consortium, M. Elkalioby, L. Fianen, L. Linhares Leite, C. Boesjes, S. Mahil, M. Franco, F. Valenzuela, C. Chaiyabutr, M. A. Lorna, F. Frez, O. Zargari, T. Hillary, H. Oon, L. Skov, M. Gupta, E. Sotiriou, N. Nguyen Loft, R. Ceovic, K. M. G. Klaassen, J. Wikström, C. Zachariae, P. Asawanonda, R. Vender, A. Carvalho, J. Song, C. Lan, J.‐T. Maul, D. Jullien, B. Hidalgo‐Matlock, A. Duvetorp, M. Gkini, D. Ioannidis, W. Veldkamp, J. Hugo, J. Barboza, A. Carugno, A. Londoño‐García, L. Schneller‐Pavelescu Apetrei, M. Ferran, F. Lafuente Urrez, N. Merino, M. Llamas Velasco, L. Puig, M. Bourcier, M. Perez Ferriols, T. Leonidze, D. Armijo, A. Eylenbosch, M. B. A. van Doorn, P. P. M. van Lumig, P. Ghislain, A. Nast, S. Lanssens, E. Sonkoly, D. J. Hijnen, E. M. Baerveldt, P. Gisondi, M. Tjioe, I. Haeck, K. Agerberg, Y. Okubo   +69 more
wiley   +1 more source

Etanercept treatment for children with refractory juvenile idiopathic arthritis

, 2011
BackgroundEtanercept has been shown to be an effective treatment for juvenile idiopathic arthritis (JIA). In this study, we evaluated the effectiveness of etanercept therapy in the treatment of refractory JIA.MethodsThis was a retrospective analysis of ...
Wu, Chih-Chiang, Yang, Kuender D., Kuo, Ho-Chang, Chih-Chiang Wu, Kuender D. Yang, Yu, Hong-Ren, Ling-Sai Chang, Ho-Chang Kuo, Hong-Ren Yu, Chang, Ling-Sai   +9 more
core   +1 more source

Unexpected multiple sclerosis‐like symptoms in a rheumatoid arthritis patient treated with Etanercept: A case report

Clinical Case Reports
Key Clinical Massage Although tumor necrosis factor (TNF) inhibitors are used to prevent autoimmune disease, but they can cause adverse effects. Multiple sclerosis syndrome is one of the rare complications following treatment with TNF inhibitor.
Ali Hosseinpour, Arsh Haj Mohamad Ebrahim Ketabforoush, Elnaz Daneshzad, Ali Babanezhad Gajouti, Samaneh Hajimollarabi   +4 more
doaj   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Systemic Therapy for Paediatric Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Current Evidence and Limitations

Journal of Paediatrics and Child Health, EarlyView.
ABSTRACT Aim The role of systemic therapy in paediatric Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) remains undefined. Management is primarily guided by observational data and variable practice patterns. This systematic review aims to integrate recent evidence and evaluate clinical outcomes associated with systemic therapies in ...
Samantha Ting, Kangjie Reuel Chua, Li‐Chuen Wong, Gloria Fong   +3 more
wiley   +1 more source

Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction

Obesity Reviews, EarlyView.
Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey, Irene Pomares‐Bri, Paula de Juan‐Maciá, Mariló Olivares‐Vicente, Enrique Barrajón‐Catalán, Vicente Micol, Enrique Roche, María Herranz‐López   +7 more
wiley   +1 more source

Etanercept for therapy-resistant macrophage activation syndrome

, 2008
Macrophage activation syndrome (MAS) is a severe, potentially fatal complication of childhood rheumatic diseases, especially systemic onset juvenile idiopathic arthritis (SoJIA). We report a 4-year-old girl with probable SoJIA who presented with MAS. She
Uensal, Erbil, YILMAZ, ŞEBNEM, Makay, BALAHAN, Tuerkyilmaz, Zeynep, ÖREN, HALE, Uenal, Nurettin   +5 more
core   +1 more source

Dermatologic Findings of RELA‐Associated Autoinflammatory Disease

Pediatric Dermatology, EarlyView.
ABSTRACT Variants in the gene RELA have been implicated in a monogenic, hereditary form of Behcet's‐like syndrome. This case series describes the dermatologic manifestations of three patients with identified RELA‐associated autoinflammatory disease.
Elizabeth Nourse, Vidya Sivaraman, Catherine G. Chung, Shoghik Akoghlanian, Esteban Fernandez Faith   +4 more
wiley   +1 more source

Off-label uses of etanercept in dermatology

, 2016
Tumour necrosis factor alpha (TNFα) is a key molecule involved in the inflammatory response and thus related to the pathogenesis of several autoimmune and autoinflammatory diseases.
Victoria de la Fuente-García, Andrés Tirado-Sánchez, Rosa María Ponce-Olivera   +2 more
core   +1 more source

NEMO‐NDAS: Case Report and Review of the Literature

Pediatric Dermatology, EarlyView.
ABSTRACT NEMO‐deleted exon 5 autoinflammatory syndrome (NEMO‐NDAS) is the result of a gain‐of‐function IKBKG pathogenic variant leading to dysregulated NF‐κB signaling and systemic inflammation. We present a case of NEMO‐NDAS in a 2‐year‐old female presenting with recurrent fevers, subcutaneous nodules, lymphadenopathy, and splenomegaly.
Angela Yang, Kristie Mar, Kimberly A. Morishita, Kevin Meesters, Antonio Torrelo, Joseph M. Lam   +5 more
wiley   +1 more source